Drug Pipeline

SX-682 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
3
Recruiting
3
Top Sponsors
Active Studies by Phase
Phase 2
1
Phase 1/2
2
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT06228053 Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration… Metastatic Castration-resistant Prostate Cancer Recruiting
Phase 1/2
NCT07002320 Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant… Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Recruiting
NCT06149481 Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine… Metastatic Colorectal Cancer Recruiting
Sponsors Running SX-682 Trials
National Cancer Institute (NCI) (1) Syntrix Biosystems, Inc. (1) Institute of Cancer Research, United Kingdom (1)
Disease Areas
Prostate Cancer (2) Colorectal Cancer (1)
Get alerts when SX-682 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free